The FDA has postponed its decision on AstraZeneca’s oral selective estrogen receptor degrader, camizestrant, after an advisory committee voted six to three that the company failed to show a clinically meaningful benefit. AstraZeneca based its application on the phase 3 SERENA‑6 “switching” study, which reported a 56% increase in progression‑free survival when patients who developed ESR1 mutations moved from an aromatase inhibitor to camizestrant. After the panel recommended against approval, AstraZeneca submitted new analyses, including data suggesting circulating tumor DNA clearance tracks with longer‑term efficacy. The company plans to present those results next week at the American Society of Clinical Oncology meeting. The FDA hasn’t set a new date for review.
That pause speaks to the agency’s capacity strains and its increasing scrutiny of oncology filings. Biogen, Savara, and Travere have all faced similar deferrals after supplementing their submissions, which means AstraZeneca’s hold‑up fits a broader trend. Regulators now have more time to test the ctDNA data, and determine whether it’s enough to change minds. If the FDA ultimately agrees with the panel, AstraZeneca’s hopes for a near‑term entrance into the oral SERD category fade fast. The company has pegged potential peak sales above $5 billion across breast cancer settings, so every extra month of waiting eats into that horizon.
There’s another way to look at this. The FDA’s slower pace, often described by sponsors as the result of “heavy workload and limited resources”, is beginning to shape how oncology programs plan their timelines. That impact grows with biomarker‑driven drugs developed for patients who have already progressed on other therapies, rather than the traditional first‑line crowd. AstraZeneca still has adjuvant and first‑line trials underway, and those upcoming results could reset the discussion if SERENA‑6 doesn’t deliver the decisive evidence regulators want. Roche’s competing oral SERD seems to be faltering, and right now, much of the class’s future rides on whether AstraZeneca can rebuild the case with stronger biomarker data. Personally, I wouldn’t bet against them, they’ve come back from tougher setbacks. For detailed drug monographs, see ClinicalRx.ai.
